Oncology Partnering Agreements in Pharma, Biotech and Diagnostics
Current Partnering
June 1, 2009 471 Pages - SKU: WWV2289777
|
|
The Oncology Partnering Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the oncology partnering agreements entered into by the worlds leading biopharma companies.
The report provides a detailed understand and analysis of how and why companies enter oncology partnering deals. The majority of deals are discovery, preclinical or clinical whereby the licensee obtains a right or an option right to license the licensors oncology technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, licensing of outcomes and often retention by the licensor of co-promotion rights.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains over 900 links to online copies of actual co-promotion and co-marketing contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of oncology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of oncology dealmaking since 2000. The chapter includes numerous case studies to enable understanding of oncology dealmaking as well as specific components such a co-promotion and option rights.
Chapter 3 provides an overview of the trends in oncology dealmaking since 2000. Chapter 4 provides a review of the leading oncology deals since 2000. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of oncology contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of oncology partnering deals signed and announced since 2003, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific oncology therapy focus. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in oncology partnering and dealmaking since 2000.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of oncology technologies, candidate compounds and products.
Key benefits
Oncology Partnering Agreements in Pharma, Biotech and Diagnostics provides the reader with the following key benefits:
- In-depth understanding of oncology deal trends since 2000
- Analysis of the structure of oncology agreements with numerous real life case studies
- Comprehensive access to over 900 actual oncology contracts entered into by the world’s biopharma companies
- Detailed access to actual oncology contracts enter into by the leading fifty bigpharma companies
- Insight into the terms included in a oncology agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
|
- Executive Summary
- Chapter 1 - Introduction
- Chapter 2 - Overview of oncology dealmaking
- 2.1. Introduction
- 2.2. The anatomy of oncology partnering
- 2.2.1. The anatomy of an oncology deal
- 2.2.1.a. Case study 1: Celgene - Array Biopharma - September 2007
- 2.2.1.b. Case study 2: Merck - Ariad - July 2007
- 2.2.1.c. Case study 3: UCB - ImClone - August 2005
- 2.3. Typical partnering terms
- 2.3.1. Headline deal values
- 2.3.2. Upfront payments
- 2.3.3. Milestone payments
- 2.3.4. Royalties
- Chapter 3 - Trends in oncology dealmaking
- 3.1. Introduction
- 3.2. Oncology partnering over the years
- 3.3. Most active oncology dealmakers
- 3.4. Bigpharma oncology dealmaking activity
- 3.5. Bigpharma not active in oncology
- 3.6. Oncology partnering by stage of development
- 3.7. Oncology partnering by deal type
- 3.7.1. Co-promotion oncology partnering
- 3.7.2. Option and evaluation oncology partnering
- 3.8. Oncology partnering by disease type
- 3.8.1. Trends in broad focus oncology partnering
- Chapter 4 - Leading oncology deals
- 4.1. Introduction
- 4.2. Top oncology deals by value
- 4.3. Top oncology involving bigpharma
- Chapter 5 - Bigpharma oncology deals
- 5.1. Introduction
- 5.2. How to use bigpharma oncology partnering deals
- 5.3. Bigpharma partnering company profiles
- Abbott
- Actavis
- Alcon Labs
- Allergan
- Amgen
- Astellas
- AstraZeneca
- Baxter International
- Bayer
- Biogen Idec
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Cephalon
- Chugai
- CSL
- Daiichi Sankyo
- Dainippon Sumitomo
- Eisai
- Eli Lilly
- Forest Laboratories
- Genentech
- Genzyme
- Gilead Sciences
- GlaxoSmithKline
- Hospira
- Johnson & Johnson
- Lundbeck
- Menarini
- Merck & Co
- Merck - Serono
- Mitsubishi Tanabe
- Mylan
- Novartis
- Novo Nordisk
- Nycomed Pharma
- Otsuka
- Pfizer
- Procter & Gamble
- Ratiopharm
- Roche
- Sanofi-Aventis
- Schering Plough
- Servier
- Shire
- Solvay
- Takeda
- Teva
- UCB
- Watson
- Wyeth
- Chapter 6 - Oncology dealmaking directory
- 6.1. Introduction
- 6.2. Company A-Z
- 6.3. By stage of development
- Discovery
- Pre-clinical
- Phase I
- Phase II
- Phase III
- Registration
- Marketed
- 6.4. By deal type
- Asset and product purchase
- Collaborative R&D
- Co-development
- Co-marketing
- Co-promotion
- Development
- Distribution
- Joint venture
- Licensing
- M&A
- Manufacturing
- Marketing
- Promotion
- Option
- Research
- Supply
- 6.5. By oncology type
- Bladder
- Breast
- Brain
- Cervical
- Colorectal
- Gastrointestinal
- Head and neck
- Kidney
- Leukemia
- Liver
- Lung
- Lymphoma
- Melanoma
- Multiple myeloma
- Ovarian
- Pancreatic
- Prostate
- Solid tumour
- Broad focus
- Diagnostics
- Drug delivery
- Chapter 7 - Oncology partnering resource center
- 7.1. Online oncology partnering
- 7.2. Oncology partnering events
- 7.3. Further reading on oncology dealmaking
- Appendices
- Appendix 1 - Deal type definitions
- Appendix 2 - Example oncology partnering agreement
- About CurrentPartnering
- Recent titles from CurrentPartnering
- Figures in report
- Figure 1: Components of the typical oncology deal structure
- Figure 2: Discovery stage average payment terms
- Figure 3: Average royalty rates payment terms
- Figure 4: Oncology partnering since 2000
- Figure 5: Most active oncology dealmakers 2003-2008
- Figure 6: Bigpharma - top 50 - oncology deals 2003 to 2008
- Figure 7: Inactive oncology dealmakers 2003-2008
- Figure 8: Oncology partnering by stage of development since 2003
- Figure 9: Oncology partnering by deal type since 2003
- Figure 10: Oncology co-promotion deals since 2003
- Figure 11: Oncology option deals since 2003
- Figure 12: Oncology partnering by disease type from 2003
- Figure 13: Trends in broad focus oncology partnering since 2003
- Figure 14: Top oncology deals by value since 2000
- Figure 15: Top 50 oncology deals signed by bigpharma value since 2000
- Figure 16: Online partnering resources
- Figure 17: Forthcoming partnering events
- Figure 18: Deal type definitions
- Figure 19: Oncology partnering between Daiichi Sankyo and ArQule, November 2008
Share this report
Other tasks Related Markets Oncology/Hematology Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
